Lu AE58054
From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name | |
---|---|
? | |
Clinical data | |
Routes of administration | ? |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | ? |
ATC code | ? |
PubChem | CID ? |
Chemical data | |
Formula | ? |
Molar mass | ? |
Lu AE58054 is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia.[1][2] As of February 2010 it is in phase II clinical trials.[2]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
- Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia
- Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease
Anticholinesterases | |||
---|---|---|---|
Others | Bifemelane • Bilobalide (Ginkgo Biloba) • Ensaculin • Latrepirdine • Lecozotan • Leteprinim • Memantine • Semagacestat | ||
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Lu_AE58054&oldid=24085"
Categories:
- Pages with script errors
- Infobox drug articles without a structure image
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Chemical articles using a fixed chemical formula
- Articles containing unverified chemical infoboxes
- 2Fix
- Antidementia agents
- Nootropics
- Serotonin antagonists